Functional CaV Pharmacology
Creative Biolabs provides custom calcium channel screening for modulator discovery, hit confirmation, selectivity assessment, and mechanism-oriented neuroscience studies, with support spanning target and cell-model planning, fluorescence-based calcium flux assays, patch clamp electrophysiology, concentration-response analysis, and collaborative data interpretation.
Discuss Your TargetScientific Rationale
Voltage-gated calcium channels translate membrane depolarization into calcium entry. Through their pore-forming CaV alpha1 subunits and associated accessory subunits, they shape neurotransmitter release, neuronal excitability, gene regulation, muscle contraction, and other calcium-dependent processes. Their subtype-specific distribution and gating behavior make assay context central to credible pharmacology.
A screening strategy therefore needs to align the biological question with channel subtype, accessory-subunit composition, cell background, holding or resting potential, stimulation protocol, and readout. Optical assays can efficiently triage compounds through kinetic calcium signals, while electrophysiology directly measures channel current and can resolve voltage dependence, kinetics, and state-dependent block. Used together, these approaches support a practical progression from scalable discovery to information-rich confirmation.
For broader program context, explore our ion channel screening services and ion channel screening technologies and platforms.
Target Coverage
Projects can focus on a defined CaV subtype or compare related channels to understand pharmacological selectivity. Final model availability and assay configuration are confirmed during project design.
| Channel family | Pore-forming subunits | Representative biological context | Screening considerations |
|---|---|---|---|
| L-type | CaV1.1, CaV1.2, CaV1.3, CaV1.4 | Muscle, sensory systems, and neuronal signaling | Subtype and tissue context; activation/inactivation protocol; accessory subunits |
| P/Q-type | CaV2.1 | Presynaptic release and cerebellar function | Direct current confirmation and comparison with other high-voltage-activated channels |
| N-type | CaV2.2 | Peripheral and central presynaptic signaling | State/use dependence, potency, and selectivity against related CaV subtypes |
| R-type | CaV2.3 | Neuronal calcium entry and transmitter release | Orthogonal pharmacology to distinguish mixed native-channel responses |
| T-type | CaV3.1, CaV3.2, CaV3.3 | Low-threshold firing, rhythmicity, and excitability | Resting potential and channel availability are critical for functional screening |
Service Capabilities
The service can be configured as a focused single-method study or as an integrated cascade that moves active compounds from optical screening into direct electrophysiological confirmation.
Kinetic intracellular calcium readouts support scalable evaluation of compound-induced inhibition or enhancement. Assay development addresses dye or sensor selection, depolarization conditions, compound timing, reference controls, signal window, and plate-level quality monitoring.
Automated or manual patch clamp can directly quantify calcium-channel current. Protocols may examine current amplitude, concentration-response behavior, current-voltage relationships, activation and inactivation, recovery, use dependence, or state dependence where relevant.
Screening can use an appropriate ready-to-use model or include custom cell-line construction and functional validation. Target sequence, species, CaV alpha1 subtype, accessory subunits, expression level, and parental-cell background are considered during model planning.
Active compounds can be retested across concentration ranges, evaluated with independent controls, and compared across calcium-channel subtypes. Orthogonal electrophysiology helps distinguish direct channel modulation from indirect changes in intracellular calcium.
Assay conditions can be tailored around compound modality, target pharmacology, stimulation paradigm, DMSO tolerance, incubation sequence, reference modulators, acceptance criteria, and downstream decisions.
Support can include trace review, normalization, concentration-response fitting, potency estimates, plate and cell quality checks, comparative pharmacology, graphical summaries, and interpretation within the limits of the selected assay.
Need a scalable primary screen, a direct current assay, or a staged cascade? Define the decision point first, then select the readout.
Plan the AssayProject Workflow
Define subtype, species, model, compounds, controls, readouts, and decision criteria.
Select or construct the cell model and confirm functional channel response.
Optimize stimulation and recording conditions, controls, and analysis windows.
Run primary testing, retest active compounds, and build concentration-response data.
Apply orthogonal or electrophysiological assays and deliver analyzed results.
Applications
Assay depth and throughput can be balanced to support discovery, optimization, and mechanism-focused studies.
Identify candidate inhibitors or activators using a scalable functional calcium readout.
Retest primary activity and establish reproducible concentration-response behavior.
Compare pharmacology across CaV family members or related ion-channel targets.
Track potency and functional behavior across compound series using consistent protocols.
Examine voltage dependence, kinetics, and state/use dependence with patch clamp.
Evaluate how calcium-channel modulation changes cellular excitability or calcium signaling in an appropriate model.
Deliverables
Available outputs depend on the selected methods and are agreed before study initiation. A project package may include experimental conditions, model and control information, quality-control summaries, raw or processed kinetic traces, current recordings, concentration-response curves, potency estimates, comparative tables, and a scientific interpretation of the results.
Assess model performance, compound behavior, and assay window before a larger campaign.
Characterize a defined set of compounds on one target or compare across selected subtypes.
Connect primary optical screening with confirmation, selectivity, and patch clamp characterization.
Related Research
Hagan and colleagues developed a calcium-flux primary assay and a patch clamp secondary assay in rat cortical neurons for L-type calcium-channel blockers. The work demonstrates the value of retaining native neuronal context during discovery while using direct current measurement to confirm and interpret primary hits.
Hagan, Rebecca, et al. “Development of Phenotypic Assays for Identifying Novel Blockers of L-Type Calcium Channels in Neurons.” Scientific Reports, vol. 11, 2021, article 456. https://doi.org/10.1038/s41598-020-80692-5
Udoh and colleagues screened phytocannabinoids against human CaV3.1, CaV3.2, and CaV3.3 T-type calcium channels expressed in HEK293 cells using a fluorescence-based calcium assay, then characterized selected active compounds with patch-clamp electrophysiology. The study illustrates a practical screening cascade in which scalable calcium-flux measurements identify candidate modulators while direct current recordings provide subtype- and state-dependent confirmation.
Udoh, Michael, et al. “The Anticonvulsant Phytocannabinoids CBGVA and CBDVA Inhibit Recombinant T-Type Channels.” Frontiers in Pharmacology, vol. 13, 2022, article 1048259. https://doi.org/10.3389/fphar.2022.1048259
FAQ
Bring the target, compounds, and decision criteria. We will help map them to a practical model and readout strategy.
Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.
